{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:50:24Z","timestamp":1781931024782,"version":"3.54.5"},"reference-count":227,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Small cell lung cancer (SCLC) is the most aggressive histological subtype of lung cancer and is characterized by rapid tumor proliferation, early dissemination, and poor prognosis. Currently, the standard first-line treatment for extensive-stage SCLC consists of platinum-based chemotherapy and immune checkpoint inhibitors. Although patients exhibit a high initial response rate to platinum-based chemotherapy, the majority develop acquired resistance within 6 months. Overcoming drug resistance and prolonging the duration of first-line therapy are critical for long-term survival in these patients. However, the definitive resistance mechanisms associated with chemotherapy and immunotherapy in SCLC remain unclear. In this context, we comprehensively review the diverse mechanisms contributing to therapeutic resistance in SCLC, including transcriptional subtype plasticity, the epithelial\u2013mesenchymal transition, an enhanced DNA damage repair capacity, dysregulated autophagy and apoptosis, the presence of cancer stem cells, alterations in the tumor microenvironment, and the aberrant expression of cellular transporters. We particularly focus on the dynamic evolution of resistance from intrinsic to acquired states and the complex interplay among these mechanisms, aiming to provide an integrated theoretical framework to guide the development of rational combination strategies to overcome therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004099","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:00:08Z","timestamp":1778299208000},"page":"1742-1760","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of resistance in small cell lung cancer"],"prefix":"10.1097","volume":"139","author":[{"given":"Wanbing","family":"Yu","sequence":"first","affiliation":[{"name":"Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangtao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute\/Beijing Chest Hospital, Capital Medical University, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runting","family":"Kang","sequence":"additional","affiliation":[{"name":"Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrui","family":"Sun","sequence":"additional","affiliation":[{"name":"Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Division 1, Beijing Life Science Academy, Beijing 102209, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyong","family":"Yu","sequence":"additional","affiliation":[{"name":"Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"R1-20260620","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260620","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"R3-20260620","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R4-20260620","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"R5-20260620","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R6-20260620","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","article-title":"Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R7-20260620","doi-asserted-by":"crossref","first-page":"522","DOI":"10.21147\/j.issn.1000-9604.2021.04.09","article-title":"Advances in novel molecular typing and precise treatment strategies for small cell lung cancer","volume":"33","author":"Bai","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"R8-20260620","article-title":"Molecular subtypes and tumor microenvironment characteristics of small-cell lung cancer associated with platinum-resistance","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R9-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225600","article-title":"Transcriptional profiling reveals mesenchymal subtypes of small cell lung cancer with activation of the epithelial-to-mesenchymal transition and worse clinical outcomes","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R10-20260620","doi-asserted-by":"crossref","first-page":"108","DOI":"10.31083\/j.fbl2703108","article-title":"Molecular subtypes of high-grade neuroendocrine carcinoma (HGNEC): What is YAP1-positive HGNEC?","volume":"27","author":"Kawai","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R11-20260620","article-title":"YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients","volume":"9","author":"Xia","year":"2014","journal-title":"PLoS One"},{"key":"R12-20260620","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3892\/ijo.2015.2948","article-title":"The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma","volume":"46","author":"Yoshikawa","year":"2015","journal-title":"Int J Oncol"},{"key":"R13-20260620","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg1850","article-title":"YAP drives fate conversion and chemoresistance of small cell lung cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci Adv"},{"key":"R14-20260620","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1038\/s41467-022-30416-2","article-title":"A conserved YAP\/Notch\/REST network controls the neuroendocrine cell fate in the lungs","volume":"13","author":"Shue","year":"2022","journal-title":"Nat Commun"},{"key":"R15-20260620","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2005.03.013","article-title":"REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis","volume":"121","author":"Ballas","year":"2005","journal-title":"Cell"},{"key":"R16-20260620","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/cas.13078","article-title":"YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer","volume":"107","author":"Horie","year":"2016","journal-title":"Cancer Sci"},{"key":"R17-20260620","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/pin.13426","article-title":"Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling","volume":"74","author":"Ito","year":"2024","journal-title":"Pathol Int"},{"key":"R18-20260620","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/cas.13013","article-title":"Loss of YAP1 defines neuroendocrine differentiation of lung tumors","volume":"107","author":"Ito","year":"2016","journal-title":"Cancer Sci"},{"key":"R19-20260620","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s13577-022-00669-6","article-title":"The role of YAP1 in small cell lung cancer","volume":"35","author":"Saito","year":"2022","journal-title":"Hum Cell"},{"key":"R20-20260620","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"R21-20260620","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cels.2022.07.006","article-title":"Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer","volume":"13","author":"Groves","year":"2022","journal-title":"Cell Syst"},{"key":"R22-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108296","article-title":"SCLC-CellMiner: A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures","volume":"33","author":"Tlemsani","year":"2020","journal-title":"Cell Rep"},{"key":"R23-20260620","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2578","article-title":"Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer","volume":"7","author":"Patel","year":"2021","journal-title":"Sci Adv"},{"key":"R24-20260620","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"R25-20260620","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2021.06.012","article-title":"Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies","volume":"154","author":"Lim","year":"2021","journal-title":"Eur J Cancer"},{"key":"R26-20260620","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","article-title":"Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: A five-arm phase 2 study","volume":"16","author":"Melichar","year":"2015","journal-title":"Lancet Oncol"},{"key":"R27-20260620","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: Primary and correlative biomarker analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R28-20260620","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/annonc\/mdu566","article-title":"Efficacy and safety of biweekly i.v. administrations of the aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: A multi-tumour, multi-institutional phase II study","volume":"26","author":"Sch\u00f6ffski","year":"2015","journal-title":"Ann Oncol"},{"key":"R29-20260620","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature22323","article-title":"Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer","volume":"545","author":"Lim","year":"2017","journal-title":"Nature"},{"key":"R30-20260620","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202300030","article-title":"Extracellular vesicles from non-neuroendocrine SCLC cells promote adhesion and survival of neuroendocrine SCLC cells","volume":"24","author":"Jimenez","year":"2024","journal-title":"Proteomics"},{"key":"R31-20260620","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/0008-5472.CAN-21-1991","article-title":"Plasticity in the absence of NOTCH uncovers a RUNX2-dependent pathway in small cell lung cancer","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res"},{"key":"R32-20260620","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","article-title":"Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R33-20260620","article-title":"Characterization of tumor-associated macrophages and the immune microenvironment in limited-stage neuroendocrine-high and -low small cell lung cancer","volume":"10","author":"Dora","year":"2021","journal-title":"Biology (Basel)"},{"key":"R34-20260620","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","article-title":"Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"R35-20260620","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/s41467-021-22336-4","article-title":"Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes","volume":"12","author":"Bebber","year":"2021","journal-title":"Nat Commun"},{"key":"R36-20260620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007343","article-title":"Systems-level network modeling of small cell lung cancer subtypes identifies master regulators and destabilizers","volume":"15","author":"Wooten","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"R37-20260620","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","article-title":"Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models","volume":"13","author":"Lissa","year":"2022","journal-title":"Nat Commun"},{"key":"R38-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051477","article-title":"Involvement of epithelial-mesenchymal transition genes in small cell lung cancer phenotypic plasticity","volume":"15","author":"Groves","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R39-20260620","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"key":"R40-20260620","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"key":"R41-20260620","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","article-title":"Epithelial-mesenchymal plasticity in cancer progression and metastasis","volume":"49","author":"Lu","year":"2019","journal-title":"Dev Cell"},{"key":"R42-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9070072","article-title":"Epigenetic regulation of the epithelial to mesenchymal transition in lung cancer","volume":"9","author":"Roche","year":"2017","journal-title":"Cancers (Basel)"},{"key":"R43-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9120171","article-title":"Regulation of EMT in colorectal cancer: A culprit in metastasis","volume":"9","author":"Vu","year":"2017","journal-title":"Cancers (Basel)"},{"key":"R44-20260620","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/1471-2407-14-855","article-title":"Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors","volume":"14","author":"Galv\u00e1n","year":"2014","journal-title":"BMC Cancer"},{"key":"R45-20260620","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1465-9921-13-104","article-title":"Snail promotes an invasive phenotype in lung carcinoma","volume":"13","author":"Merikallio","year":"2012","journal-title":"Respir Res"},{"key":"R46-20260620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100249","article-title":"Tumor cell heterogeneity in small cell lung cancer (SCLC): Phenotypical and functional differences associated with epithelial-mesenchymal transition (EMT) and DNA methylation changes","volume":"9","author":"Krohn","year":"2014","journal-title":"PLoS One"},{"key":"R47-20260620","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.lungcan.2014.10.007","article-title":"Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines","volume":"86","author":"Hassan","year":"2014","journal-title":"Lung Cancer"},{"key":"R48-20260620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13577-016-0149-3","article-title":"Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: Significance of inactive Notch signaling and expression of achaete-scute complex homologue 1","volume":"30","author":"Ito","year":"2017","journal-title":"Hum Cell"},{"key":"R49-20260620","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-014-0087-z","article-title":"Notch signaling and EMT in non-small cell lung cancer: Biological significance and therapeutic application","volume":"7","author":"Yuan","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R50-20260620","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1759-7714.12297","article-title":"Notch1 controls cell chemoresistance in small cell lung carcinoma cells","volume":"7","author":"Hassan","year":"2016","journal-title":"Thorac Cancer"},{"key":"R51-20260620","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R52-20260620","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2021.06.022","article-title":"A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC","volume":"16","author":"Hann","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R53-20260620","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: Results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R54-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg Chem"},{"key":"R55-20260620","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2147\/DDDT.S205633","article-title":"A novel mutation panel for predicting etoposide resistance in small-cell lung cancer","volume":"13","author":"Qiu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R56-20260620","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mco2.103","article-title":"Targeting DNA repair pathway in cancer: Mechanisms and clinical application","volume":"2","author":"Wang","year":"2021","journal-title":"MedComm (2020)"},{"key":"R57-20260620","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: An intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"R58-20260620","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/2159-8290.CD-13-0891","article-title":"PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair","volume":"4","author":"Hu","year":"2014","journal-title":"Cancer Discov"},{"key":"R59-20260620","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ccr.2013.03.025","article-title":"Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation","volume":"23","author":"Li","year":"2013","journal-title":"Cancer Cell"},{"key":"R60-20260620","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res"},{"key":"R61-20260620","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.11106","article-title":"The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer","volume":"105","author":"Hansen","year":"2003","journal-title":"Int J Cancer"},{"key":"R62-20260620","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12885-019-5798-7","article-title":"MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer","volume":"19","author":"Lai","year":"2019","journal-title":"BMC Cancer"},{"key":"R63-20260620","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"R64-20260620","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","article-title":"Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer","volume":"19","author":"Cardnell","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R65-20260620","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: A randomized, double-blind, phase 3 study","volume":"16","author":"Ai","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R66-20260620","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2022.07.007","article-title":"Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial","volume":"171","author":"Woll","year":"2022","journal-title":"Lung Cancer"},{"key":"R67-20260620","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol"},{"key":"R68-20260620","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/1078-0432.CCR-18-2014","article-title":"A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors","volume":"25","author":"Atrafi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R69-20260620","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small-cell lung cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov"},{"key":"R70-20260620","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol"},{"key":"R71-20260620","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R72-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040727","article-title":"PARP inhibitors in small-cell lung cancer: Rational combinations to improve responses","volume":"13","author":"Knelson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R73-20260620","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","article-title":"Veliparib in combination with carboplatin and etoposide in patients with treatment-na\u00efve extensive-stage small cell lung cancer: A phase 2 randomized study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R74-20260620","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R75-20260620","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","article-title":"Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy","volume":"24","author":"Reed","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"R76-20260620","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"R77-20260620","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin Chem"},{"key":"R78-20260620","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"R79-20260620","article-title":"Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population","volume":"18","author":"Wu","year":"2023","journal-title":"PLoS One"},{"key":"R80-20260620","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/JTO.0b013e3181734f24","article-title":"Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: A retrospective study","volume":"3","author":"Ceppi","year":"2008","journal-title":"J Thorac Oncol"},{"key":"R81-20260620","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2007.07.023","article-title":"Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer","volume":"59","author":"Lee","year":"2008","journal-title":"Lung Cancer"},{"key":"R82-20260620","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JTO.0b013e3181ca063b","article-title":"ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: Distribution and impact on survival","volume":"5","author":"Skov","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R83-20260620","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1158\/1078-0432.CCR-07-1612","article-title":"Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis","volume":"14","author":"Yu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R84-20260620","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","article-title":"EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair","volume":"39","author":"Koyen","year":"2020","journal-title":"Oncogene"},{"key":"R85-20260620","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","article-title":"Epigenetic landscape of small cell lung cancer: Small image of a giant recalcitrant disease","volume":"83","author":"Khan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R86-20260620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071670","article-title":"Genomic deregulation of the E2F\/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer","volume":"8","author":"Coe","year":"2013","journal-title":"PLoS One"},{"key":"R87-20260620","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/JTO.0b013e318298762f","article-title":"EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation","volume":"8","author":"Hubaux","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R88-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102768","article-title":"The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer","volume":"128","author":"Scattolin","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"R89-20260620","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin Epigenetics"},{"key":"R90-20260620","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.01.013","article-title":"Awakening of \u201cSchlafen11\u201d to tackle chemotherapy resistance in SCLC","volume":"31","author":"Berns","year":"2017","journal-title":"Cancer Cell"},{"key":"R91-20260620","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"R92-20260620","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-23-3383","article-title":"A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer","volume":"30","author":"Choudhury","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R93-20260620","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41401-021-00817-y","article-title":"FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11","volume":"43","author":"Yin","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R94-20260620","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-016-0575-6","article-title":"Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2","volume":"16","author":"Niu","year":"2017","journal-title":"Mol Cancer"},{"key":"R95-20260620","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.7150\/thno.33680","article-title":"CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter","volume":"9","author":"Qiu","year":"2019","journal-title":"Theranostics"},{"key":"R96-20260620","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/1759-7714.14862","article-title":"Wee1 epigenetically modulates H2B mono-ubiquitination at K120 lysine and DNA double-strand break repair through phosphorylation of H2BY37-dependent manner in small-cell lung cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Thorac Cancer"},{"key":"R97-20260620","first-page":"194","article-title":"Treatment with the Chk1 inhibitor G\u00f66976 enhances cisplatin cytotoxicity in SCLC cells","volume":"40","author":"Thompson","year":"2012","journal-title":"Int J Oncol"},{"key":"R98-20260620","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jtho.2019.01.028","article-title":"Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death","volume":"14","author":"Hsu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R99-20260620","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12967-023-04338-6","article-title":"Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: Recent progress and future directions","volume":"21","author":"Zhang","year":"2023","journal-title":"J Transl Med"},{"key":"R100-20260620","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2697","article-title":"Autophagy: Cellular and molecular mechanisms","volume":"221","author":"Glick","year":"2010","journal-title":"J Pathol"},{"key":"R101-20260620","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrm2239","article-title":"Self-eating and self-killing: Crosstalk between autophagy and apoptosis","volume":"8","author":"Maiuri","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R102-20260620","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R103-20260620","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"R104-20260620","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1200\/JCO.1999.17.9.2941","article-title":"Dysregulation of apoptosis in cancer","volume":"17","author":"Reed","year":"1999","journal-title":"J Clin Oncol"},{"key":"R105-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109415","article-title":"Autophagy: A novel mechanism of chemoresistance in cancers","volume":"119","author":"Li","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R106-20260620","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/cdd.2010.191","article-title":"The Beclin 1 network regulates autophagy and apoptosis","volume":"18","author":"Kang","year":"2011","journal-title":"Cell Death Differ"},{"key":"R107-20260620","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1159\/000481754","article-title":"Intensified Beclin-1 mediated by low expression of Mir-30a-5p promotes chemoresistance in human small cell lung cancer","volume":"43","author":"Yang","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"Suppl 1","key":"R108-20260620","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1038\/onc.2009.51","article-title":"The autophagy effector Beclin 1: A novel BH3-only protein","volume":"27","author":"Sinha","year":"2008","journal-title":"Oncogene"},{"key":"R109-20260620","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jare.2023.12.020","article-title":"HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy","volume":"66","author":"Shen","year":"2024","journal-title":"J Adv Res"},{"key":"R110-20260620","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12943-024-02145-1","article-title":"Overcoming multi-drug resistance in SCLC: A synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT\/BCL2\/BECN1 pathway","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"R111-20260620","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"key":"R112-20260620","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1038\/sj.onc.1205941","article-title":"Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification","volume":"21","author":"Shivapurkar","year":"2002","journal-title":"Oncogene"},{"key":"R113-20260620","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2007.11.005","article-title":"TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2\/DR5 expression in the absence of caspase-8","volume":"60","author":"Belyanskaya","year":"2008","journal-title":"Lung Cancer"},{"key":"R114-20260620","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R115-20260620","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/theoncologist.2009-0026","article-title":"New advances in the second-line treatment of small cell lung cancer","volume":"14","author":"Hurwitz","year":"2009","journal-title":"Oncologist"},{"key":"R116-20260620","first-page":"1036","article-title":"Small cell carcinomas of the lung express the Bcl-2 protein","volume":"145","author":"Ben-Ezra","year":"1994","journal-title":"Am J Pathol"},{"key":"R117-20260620","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0169-5002(96)00568-5","article-title":"Expression of bcl-2--protein in small cell lung cancer","volume":"15","author":"Kaiser","year":"1996","journal-title":"Lung Cancer"},{"key":"R118-20260620","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ijc.10096","article-title":"Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines","volume":"97","author":"Sartorius","year":"2002","journal-title":"Int J Cancer"},{"key":"R119-20260620","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2004.10.148","article-title":"Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer","volume":"22","author":"Rudin","year":"2004","journal-title":"J Clin Oncol"},{"key":"R120-20260620","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/annonc\/mdf124","article-title":"A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer","volume":"13","author":"Rudin","year":"2002","journal-title":"Ann Oncol"},{"key":"R121-20260620","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2007.14.3461","article-title":"Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R122-20260620","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R123-20260620","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R124-20260620","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","article-title":"A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R125-20260620","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2011.05.005","article-title":"A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer","volume":"74","author":"Paik","year":"2011","journal-title":"Lung Cancer"},{"key":"R126-20260620","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy","volume":"8","author":"Inoue-Yamauchi","year":"2017","journal-title":"Nat Commun"},{"key":"R127-20260620","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737","volume":"67","author":"Tahir","year":"2007","journal-title":"Cancer Res"},{"key":"R128-20260620","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41416-023-02219-9","article-title":"Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer","volume":"128","author":"Valko","year":"2023","journal-title":"Br J Cancer"},{"key":"R129-20260620","article-title":"CDK4\/6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer","volume":"11","author":"Wen","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"R130-20260620","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41419-024-06724-4","article-title":"CDK9 inhibition as an effective therapy for small cell lung cancer","volume":"15","author":"Valdez Capuccino","year":"2024","journal-title":"Cell Death Dis"},{"key":"R131-20260620","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-023-01315-2","article-title":"Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR\/Cas9 screening","volume":"9","author":"Deng","year":"2023","journal-title":"Cell Death Discov"},{"key":"R132-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112362","article-title":"ABC transporters in cancer stem cells: Beyond chemoresistance","volume":"18","author":"Begicevic","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R133-20260620","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bcp.2018.12.010","article-title":"Lung cancer stem cells: Origin, features, maintenance mechanisms and therapeutic targeting","volume":"160","author":"Heng","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"R134-20260620","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2016.01.012","article-title":"Lung cancer stem cells: The root of resistance","volume":"372","author":"MacDonagh","year":"2016","journal-title":"Cancer Lett"},{"key":"R135-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci"},{"key":"R136-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235912","article-title":"Regulation of metabolic plasticity in cancer stem cells and implications in cancer therapy","volume":"14","author":"Papadaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R137-20260620","first-page":"16","article-title":"Cancer stem cells in small cell lung cancer","volume":"5","author":"Codony-Servat","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R138-20260620","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cllc.2016.05.015","article-title":"Cancer stem cells, epithelial to mesenchymal markers, and circulating tumor cells in small cell lung cancer","volume":"17","author":"Pore","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R139-20260620","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1158\/0008-5472.CAN-13-1541","article-title":"CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist","volume":"74","author":"Sarvi","year":"2014","journal-title":"Cancer Res"},{"key":"R140-20260620","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","article-title":"Identification and expansion of the tumorigenic lung cancer stem cell population","volume":"15","author":"Eramo","year":"2008","journal-title":"Cell Death Differ"},{"key":"R141-20260620","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00262-021-02998-1","article-title":"Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes","volume":"71","author":"Kursunel","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R142-20260620","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cas.12045","article-title":"Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy","volume":"104","author":"Kubo","year":"2013","journal-title":"Cancer Sci"},{"key":"R143-20260620","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2021.02.002","article-title":"A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker","volume":"154","author":"Heng","year":"2021","journal-title":"Lung Cancer"},{"key":"R144-20260620","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-17-1932","article-title":"Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel \u03b12\u03b41 subunit-mediated chemotherapy resistance in small-cell lung cancer","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R145-20260620","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1515\/raon-2015-0027","article-title":"The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer","volume":"50","author":"Sodja","year":"2016","journal-title":"Radiol Oncol"},{"key":"R146-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174147","article-title":"The role of CD44 in cancer chemoresistance: A concise review","volume":"903","author":"Yaghobi","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R147-20260620","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41420-024-01871-1","article-title":"SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids","volume":"10","author":"Roy","year":"2024","journal-title":"Cell Death Discov"},{"key":"R148-20260620","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2013.01.022","article-title":"Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer","volume":"23","author":"Dong","year":"2013","journal-title":"Cancer Cell"},{"key":"R149-20260620","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41388-022-02391-x","article-title":"PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma","volume":"41","author":"Thirusangu","year":"2022","journal-title":"Oncogene"},{"key":"R150-20260620","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cac2.12351","article-title":"A non-metabolic function of hexokinase 2 in small cell lung cancer: Promotes cancer cell stemness by increasing USP11-mediated CD133 stability","volume":"42","author":"Wang","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R151-20260620","article-title":"Cancer stem cells in small cell lung cancer cell line H446: Higher dependency on oxidative phosphorylation and mitochondrial substrate-level phosphorylation than non-stem cancer cells","volume":"11","author":"Gao","year":"2016","journal-title":"PLoS One"},{"key":"R152-20260620","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s43018-022-00358-1","article-title":"Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer","volume":"3","author":"Guo","year":"2022","journal-title":"Nat Cancer"},{"key":"R153-20260620","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)","volume":"51","author":"Katoh","year":"2017","journal-title":"Int J Oncol"},{"key":"R154-20260620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ccell.2015.06.011","article-title":"Altering the course of small cell lung cancer: Targeting cancer stem cells via LSD1 inhibition","volume":"28","author":"Stewart","year":"2015","journal-title":"Cancer Cell"},{"key":"R155-20260620","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/cas.15653","article-title":"Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation","volume":"114","author":"Liang","year":"2023","journal-title":"Cancer Sci"},{"key":"R156-20260620","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12032-022-01859-w","article-title":"NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer","volume":"39","author":"Wang","year":"2022","journal-title":"Med Oncol"},{"key":"R157-20260620","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2022.11.006","article-title":"The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy","volume":"87","author":"Guo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R158-20260620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol"},{"key":"R159-20260620","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol Cancer"},{"key":"R160-20260620","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R161-20260620","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2017.01.003","article-title":"The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation","volume":"106","author":"Iriki","year":"2017","journal-title":"Lung Cancer"},{"key":"R162-20260620","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s13577-023-00895-6","article-title":"Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage","volume":"36","author":"Mito","year":"2023","journal-title":"Hum Cell"},{"key":"R163-20260620","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41419-022-05336-0","article-title":"NLRP6 is required for cancer-derived exosome-modified macrophage M2 polarization and promotes metastasis in small cell lung cancer","volume":"13","author":"Rao","year":"2022","journal-title":"Cell Death Dis"},{"key":"R164-20260620","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"R165-20260620","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"R166-20260620","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10120-021-01270-w","article-title":"CAF promotes chemoresistance through NRP2 in gastric cancer","volume":"25","author":"Yang","year":"2022","journal-title":"Gastric Cancer"},{"key":"R167-20260620","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.7150\/thno.25541","article-title":"Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19","volume":"8","author":"Ren","year":"2018","journal-title":"Theranostics"},{"key":"R168-20260620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2020.05.014","article-title":"Tumor-secreted exosomal lncRNA POU3F3 promotes cisplatin resistance in ESCC by inducing fibroblast differentiation into CAFs","volume":"18","author":"Tong","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"R169-20260620","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ijc.32608","article-title":"Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells","volume":"146","author":"Deng","year":"2020","journal-title":"Int J Cancer"},{"key":"R170-20260620","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3349\/ymj.2022.63.3.229","article-title":"MEG3 lncRNA from exosomes released from cancer-associated fibroblasts enhances cisplatin chemoresistance in SCLC via a MiR-15a-5p\/CCNE1 axis","volume":"63","author":"Sun","year":"2022","journal-title":"Yonsei Med J"},{"key":"R171-20260620","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41598-024-52687-z","article-title":"Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer","volume":"14","author":"Lu","year":"2024","journal-title":"Sci Rep"},{"key":"R172-20260620","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1096326","article-title":"Assessing the epithelial-to-mesenchymal plasticity in a small cell lung carcinoma (SCLC) and lung fibroblasts co-culture model","volume":"10","author":"Dhungel","year":"2023","journal-title":"Front Mol Biosci"},{"key":"R173-20260620","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/path.6240","article-title":"A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction","volume":"262","author":"Pastorino","year":"2024","journal-title":"J Pathol"},{"key":"R174-20260620","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/cs1020417","article-title":"Extracellular matrix regulation of drug resistance in small-cell lung cancer","volume":"102","author":"Rintoul","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"R175-20260620","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(00)00421-6","article-title":"The role of extracellular matrix in small-cell lung cancer","volume":"2","author":"Rintoul","year":"2001","journal-title":"Lancet Oncol"},{"key":"R176-20260620","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo","volume":"5","author":"Sethi","year":"1999","journal-title":"Nat Med"},{"key":"R177-20260620","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/sj.cdd.4401849","article-title":"ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase","volume":"13","author":"Hodkinson","year":"2006","journal-title":"Cell Death Differ"},{"key":"R178-20260620","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1158\/0008-5472.CAN-05-0058","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin pathway but not the MEK\/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy","volume":"65","author":"Tsurutani","year":"2005","journal-title":"Cancer Res"},{"key":"R179-20260620","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jmb.2008.12.021","article-title":"The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B","volume":"386","author":"Gioia","year":"2009","journal-title":"J Mol Biol"},{"key":"R180-20260620","article-title":"MMP9 expression correlates with cisplatin resistance in small cell lung cancer patients","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R181-20260620","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2022.11.005","article-title":"Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response","volume":"87","author":"Khan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R182-20260620","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/13543780902804249","article-title":"CXCR4 chemokine receptor antagonists: Perspectives in SCLC","volume":"18","author":"Burger","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R183-20260620","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/sj.onc.1208621","article-title":"CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells","volume":"24","author":"Hartmann","year":"2005","journal-title":"Oncogene"},{"key":"R184-20260620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01695-6","article-title":"MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4\/FOXM1\/RRM2 axis","volume":"22","author":"Khan","year":"2023","journal-title":"Mol Cancer"},{"key":"R185-20260620","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1158\/0008-5472.CAN-10-0996","article-title":"Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer","volume":"70","author":"Kohmo","year":"2010","journal-title":"Cancer Res"},{"key":"R186-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110413","article-title":"Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer","volume":"27","author":"Zhu","year":"2024","journal-title":"iScience"},{"key":"R187-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109824","article-title":"Activation of the TGF-\u03b21\/EMT signaling pathway by claudin-1 overexpression reduces doxorubicin sensitivity in small cell lung cancer SBC-3 cells","volume":"751","author":"Nagaoka","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"R188-20260620","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.drudis.2019.06.010","article-title":"Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer","volume":"24","author":"Kulkarni","year":"2019","journal-title":"Drug Discov Today"},{"key":"R189-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184608","article-title":"Extracellular vesicle-associated miRNAs and chemoresistance: A systematic review","volume":"13","author":"Campos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R190-20260620","article-title":"Exosomal miR-92b-3p promotes chemoresistance of small cell lung cancer through the PTEN\/AKT pathway","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R191-20260620","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2147\/IJN.S407116","article-title":"Extracellular cesicles derived circSH3PXD2A inhibits chemoresistance of small cell lung cancer by miR-375-3p\/YAP1","volume":"18","author":"Chao","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"R192-20260620","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119878","article-title":"The association of ABC proteins with multidrug resistance in cancer","volume":"1872","author":"Marques","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"R193-20260620","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.tiv.2008.04.005","article-title":"Development of taxane resistance in a panel of human lung cancer cell lines","volume":"22","author":"Breen","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"R194-20260620","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oxfordjournals.annonc.a010681","article-title":"Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues","volume":"7","author":"Dingemans","year":"1996","journal-title":"Ann Oncol"},{"key":"R195-20260620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s004080000091","article-title":"Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression","volume":"180","author":"Hsia","year":"2002","journal-title":"Lung"},{"key":"R196-20260620","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1023\/A:1013133801173","article-title":"Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression","volume":"12","author":"Kao","year":"2001","journal-title":"Ann Oncol"},{"key":"R197-20260620","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bjc.1998.241","article-title":"Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer","volume":"77","author":"Kreisholt","year":"1998","journal-title":"Br J Cancer"},{"key":"R198-20260620","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0969-8051(03)00058-1","article-title":"To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression","volume":"30","author":"Kuo","year":"2003","journal-title":"Nucl Med Biol"},{"key":"R199-20260620","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00408-004-2532-1","article-title":"Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer","volume":"183","author":"Yeh","year":"2005","journal-title":"Lung"},{"key":"R200-20260620","first-page":"673","article-title":"Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response","volume":"5","author":"Young","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R201-20260620","first-page":"2079","article-title":"Multidrug resistance-associated protein (MRP) gene expression in human lung cancer","volume":"16","author":"Narasaki","year":"1996","journal-title":"Anticancer Res"},{"key":"R202-20260620","first-page":"115","article-title":"Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer","volume":"3","author":"Campling","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R203-20260620","first-page":"1798","article-title":"Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels","volume":"7","author":"Young","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R204-20260620","first-page":"2279","article-title":"Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung","volume":"4","author":"Wright","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R205-20260620","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bcp.2005.05.005","article-title":"Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin","volume":"70","author":"Singhal","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"R206-20260620","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/0008-5472.991.65.3","article-title":"RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer","volume":"65","author":"Stuckler","year":"2005","journal-title":"Cancer Res"},{"key":"R207-20260620","first-page":"713","article-title":"Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76","volume":"22","author":"Awasthi","year":"2003","journal-title":"Int J Oncol"},{"key":"R208-20260620","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.febslet.2006.03.038","article-title":"Determinants of differential doxorubicin sensitivity between SCLC and NSCLC","volume":"580","author":"Singhal","year":"2006","journal-title":"FEBS Lett"},{"key":"R209-20260620","first-page":"1505","article-title":"Role of RLIP76 in doxorubicin resistance in lung cancer","volume":"34","author":"Vatsyayan","year":"2009","journal-title":"Int J Oncol"},{"key":"R210-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041038","article-title":"Pathologic complete response in urothelial carcinoma patients receiving neoadjuvant immune checkpoint inhibitors: A meta-analysis","volume":"11","author":"Rizzo","year":"2022","journal-title":"J Clin Med"},{"key":"R211-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: Recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R212-20260620","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: Progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"R213-20260620","first-page":"55","article-title":"Mechanisms of immunotherapy resistance in small cell lung cancer","volume":"7","author":"Nie","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"R214-20260620","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","article-title":"Immunotherapy for small cell lung cancer: Mechanisms of resistance","volume":"19","author":"Hamilton","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"R215-20260620","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-23-1159","article-title":"Facts and hopes on cancer immunotherapy for small cell lung cancer","volume":"30","author":"Zugazagoitia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R216-20260620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123729","article-title":"Primary and acquired resistance to immunotherapy in lung cancer: Unveiling the ,mechanisms underlying of immune checkpoint blockade therapy","volume":"12","author":"Boyero","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R217-20260620","article-title":"MYC activation impairs cell-intrinsic IFN\u03b3 signaling and confers resistance to anti-PD1\/PD-L1 therapy in lung cancer","volume":"4","author":"Alburquerque-Bejar","year":"2023","journal-title":"Cell Rep Med"},{"key":"R218-20260620","article-title":"Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer","volume":"6","author":"Luo","year":"2025","journal-title":"MedComm (2020)"},{"key":"R219-20260620","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-025-01667-5","article-title":"Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer","volume":"18","author":"Yoo","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R220-20260620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"R221-20260620","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","article-title":"Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC","volume":"17","author":"Nguyen","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R222-20260620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-024-00784-7","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9","author":"Ajay","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"R223-20260620","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R224-20260620","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R225-20260620","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/13543784.2025.2512566","article-title":"Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer","volume":"34","author":"Wespiser","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"R226-20260620","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R227-20260620","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:01:05Z","timestamp":1781928065000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":227,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004099","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2025-10-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}